Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism.
Zhou Q, Lin M, Feng X, Ma F, Zhu Y, Liu X, Qu C, Sui H, Sun B, Zhu A, Zhang H, Huang H, Gao Z, Zhao Y, Sun J, Bai Y, Jin J, Hong X, Zou C, Zhang Z.
Zhou Q, et al. Among authors: liu x.
J Exp Med. 2020 Aug 3;217(8):e20191779. doi: 10.1084/jem.20191779.
J Exp Med. 2020.
PMID: 32453420
Free PMC article.